PhoreMost Ltd., a UK-based biopharmaceutical company, has entered into a multi-project target discovery collaboration with Roche, a leading biotechnology company. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.   PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Ro...